Jim Cregg

Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy

Matthew Holderfield, Bianca J. Lee, Jingjing Jiang et al. · Nature · 2024 · 318 citations · Full text

Medicine, Oncology, Pharmacology +16

Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS

Christopher J. Schulze, Kyle J. Seamon, Yulei Zhao et al. · Science · 2023 · 232 citations · Full text

Medicine, Medicinal Chemistry, Oncology +17

Abstract 3595: RMC-6291, a next-generation tri-complex KRASG12C(ON) inhibitor, outperforms KRASG12C(OFF) inhibitors in preclinical models of KRASG12C cancers

Robert J. Nichols, Yu Chi Yang, Jim Cregg et al. · Cancer Research · 2022 · 34 citations

Medicine, Oncology, Pharmacology +17

Abstract 1260: First-in-class, orally bioavailable KRASG12V(ON) tri-complex inhibitors, as single agents and in combinations, drive profound anti-tumor activity in preclinical models of KRASG12V mutant cancers

Elena S. Koltun, Jim Cregg, Meghan A. Rice et al. · Cancer Research · 2021 · 33 citations

Medicine, Oncology, Pharmacology +16

Abstract 3597: Direct targeting of KRASG12X mutant cancers with RMC-6236, a first-in-class, RAS-selective, orally bioavailable, tri-complex RASMULTI(ON) inhibitor

Elena S. Koltun, Meghan A. Rice, W. Clay Gustafson et al. · Cancer Research · 2022 · 31 citations

Medicine, Oncology, Pharmacology +15